BioInvent: Exceptional PFS in Ovarian Cancer - Redeye

The most recent readout with BI-1808 in combination with pembrolizumab in ovarian cancer, released yesterday evening, further strengthens our conviction in the combination. The preliminary PFS of 10.3 months is exceptional. BI-1808 + pembrolizumab increasingly looks like a promising new therapeutic option for multiple cancers.

Länk till analysen i sin helhet: https://www.redeye.se/research/1169045/bioinvent-exceptional-pfs-in-ovarian-cancer?utm_source=finwire&utm_medium=RSS